SOURCE: PacificHealth Laboratories, Inc.

PacificHealth Laboratories, Inc.

March 23, 2011 09:00 ET

PacificHealth Laboratories Announces Private Sale of Stock and Election of New Board Member

MATAWAN, NJ--(Marketwire - March 23, 2011) - PacificHealth Laboratories, Inc. (OTCQB: PHLI), a nutrition technology company, announced today that the Company completed a private placement of its common stock resulting in net proceeds to the Company of $450,000. The private placement was sold as 180,000 units with each unit representing ten shares of the Company's common stock at a purchase price of $0.25 per share, warrants to purchase five additional shares of common stock at $0.31 per share, and warrants to purchase one additional share of common stock at $0.38 per share. The President and CEO, Fred Duffner, and director, Dr. Robert Portman, participated in the private placement. There were no fees or expenses associated with this placement. Yesterday's closing trading price of the Company's stock was $0.225 per share. 

Fred Duffner, CEO and President of PacificHealth Laboratories said, "The additional capital raised ensures that we do not lose any momentum this year as we execute our aggressive plan for making the Company profitable in 2011."

The Company also announced the election of Lee Feldman to the Board of Directors. Mr. Feldman is the Managing Partner of Twin Lakes Capital, a private equity firm focused on branded consumer products, media and business services. He is also the CEO of MacKenzie-Childs, the iconic American luxury home furnishings and personal accessories company that was acquired by Twin Lakes. Mr. Feldman also serves on the Boards of GVC Holdings, LRN, RM Auctions and MacKenzie-Childs. He holds a B.A. and J.D. from Columbia University. 

Fred Duffner said, "We welcome Lee as a new Board member. His experience will be invaluable as we grow the Company."

About PacificHealth:
PacificHealth Laboratories, Inc. (OTCQB: PHLI), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI's principal areas of focus include sports performance and weight loss. To learn more, visit

Notice: This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements." These statements can be identified by introductory words such as "expects," "plans," "will," "estimates," "forecasts," "projects," or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such as general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.

Contact Information